File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Phase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826)

TitlePhase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826)
Authors
Hamilton, EMeisel, JAlemany, CVirginia, BLin, NWesolowski, RMathauda-Sahota, GMakower, DLawrence, JFaltaos, DMitri, ZSabanathan, DClark, DPluard, THui, RMcCarthy, NPatel, M
Issue Date1-Oct-2022
PublisherElsevier
Citation
European Journal of Cancer, 2022, v. 174, n. S1, p. 36-36 How to Cite?
DOI: http://dx.doi.org/10.1016/S0959-8049(22)00896-6
Persistent Identifierhttp://hdl.handle.net/10722/338831
ISSN
0959-8049
2023 Impact Factor: 7.6
2023 SCImago Journal Rankings: 2.501

 

DC FieldValueLanguage
dc.contributor.authorHamilton, E-
dc.contributor.authorMeisel, J-
dc.contributor.authorAlemany, C-
dc.contributor.authorVirginia, B-
dc.contributor.authorLin, N-
dc.contributor.authorWesolowski, R-
dc.contributor.authorMathauda-Sahota, G-
dc.contributor.authorMakower, D-
dc.contributor.authorLawrence, J-
dc.contributor.authorFaltaos, D-
dc.contributor.authorMitri, Z-
dc.contributor.authorSabanathan, D-
dc.contributor.authorClark, D-
dc.contributor.authorPluard, T-
dc.contributor.authorHui, R-
dc.contributor.authorMcCarthy, N-
dc.contributor.authorPatel, M-
dc.date.accessioned2024-03-11T10:31:52Z-
dc.date.available2024-03-11T10:31:52Z-
dc.date.issued2022-10-01-
dc.identifier.citationEuropean Journal of Cancer, 2022, v. 174, n. S1, p. 36-36-
dc.identifier.issn0959-8049-
dc.identifier.urihttp://hdl.handle.net/10722/338831-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofEuropean Journal of Cancer-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titlePhase 1b results from OP-1250-001, a dose escalation and dose expansion study of OP-1250, an oral CERAN, in subjects with advanced and/or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer (NCT04505826)-
dc.typeArticle-
dc.identifier.doi10.1016/S0959-8049(22)00896-6-
dc.identifier.scopuseid_2-s2.0-85140470232-
dc.identifier.volume174-
dc.identifier.issueS1-
dc.identifier.spage36-
dc.identifier.epage36-
dc.identifier.eissn1879-0852-
dc.identifier.issnl0959-8049-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats